3-24 | 24th March is the World Tuberculosis (TB) Day. A new briefing paper by Médecins Sans Frontières (MSF) outlines why the alarming spread of deadly strains of drug-resistant tuberculosis (DR-TB) is one of the biggest global health threats we face today. It calls on governments, pharmaceutical companies and researchers to mobilise urgently to save more lives and find new treatments to stem the virulent disease. Every year, around eight million people worldwide fall ill with tuberculosis (TB) and 1.3 million people die from the infectious airborne disease.
1-6 | Visit “See What We See” multimedia website The fight against HIV/AIDS has been hailed as one of the most successful public health projects in human history, but teams from Médecins Sans Frontières (MSF) see the revolution as unfulfilled for millions of people excluded from treatment.
8-19 | More steps need to be taken to secure access to one-pill-once-a-day HIV treatment The recent invalidation by China’s State Intellectual Property Office (SIPO) of one of the patents on tenofovir disoproxil fumarate (TDF), an essential medicine to treat HIV and hepatitis B, is a welcome step to reduce barriers that prevent access to affordable generic versions in China, according to Médecins Sans Frontières (MSF). “We are pleased that SIPO has invalidated a pat
As US FDA approves promising new HIV drug dolutegravir, MSF asks when people in developing countries will have access
8-16 | As the US Food and Drug Administration approved the new HIV drug dolutegravir on 13 Aug, Médecins Sans Frontières (MSF) questioned when people in developing countries would be able to access this promising new drug. Studies have shown dolutegravir, a drug from the potent new integrase inhibitor class of drugs, to be well-tolerated and extremely effective in stopping replication of the HIV virus, with a high barrier to HIV resistance.
7-2 | MSF pricing analysis also extends to HIV diagnostic and monitoring tools